Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Clinical trial NCT03373019 · UNKNOWN

Trial details

NCT number: NCT03373019
Sponsor: Fudan University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Chidamide Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasm by Histology Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Cyclophosphamide Rituximab

Start date: 2017-12-21
Primary completion: 2019-06-30
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.